Skip to content
The Policy VaultThe Policy Vault

Alecensa (alectinib) — Medica

Large B-Cell Lymphoma

Initial criteria

  • age ≥ 18 years
  • anaplastic lymphoma kinase (ALK)-positive disease
  • relapsed or refractory disease

Approval duration

1 year